Medicine
Medroxyprogesterone 150 mg/1 mL injectable suspension
Medroxyprogesterone 150 mg/1 mL injectable suspension is a generic prescription medicine for intramuscular use, made by 10 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Medroxyprogesterone acetate injectable suspension, USP is supplied as follows…
Key facts
- Active ingredient (INN)
- Medroxyprogesterone
- Brand
- Sold under the generic name
- Strength
- 150 mg/1 mL
- Dosage form
- Injectable suspension
- Route
- Intramuscular
- Packs
- 1 vial of 1 mL, 25 vials of 1 mL, 1 syringe of 1 mL and 20 more
- Manufacturers
- EugiaIndiaSun Pharmaceutical IndustriesIndiaAmneal PharmaceuticalsPrasco LaboratoriesA-S Medication SolutionsAmneal Pharmaceuticals NYHikma PharmaceuticalsMylan InstitutionalXiromedRemedyrepack
- Origin register
- US FDA, United States
- Storage
- Medroxyprogesterone acetate injectable suspension, USP is supplied as follows: Package Configuration Strength NDC Medroxyprogesterone acetate injectable suspension, USP, 150 mg/mL, 1 mL Prefilled Syringe packed with 22 gauge x 1 1/2 inch Terumo SurGuard ® Needles 1 mL prefilled syringe 150 mg/mL NDC 62756-091-40 Stored at controlled room temperature 20° to 25°C (68° to 77°F), excursions permitted…
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- G03AC06 Medroxyprogesterone
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 12 October 2018
- Identifiers
- RxCUI 1000153, 1000126DailyMed set ID 01e28bef-9758-40cf-a4ff-86ae9f4f5105, 6457d70a-2f25-4935-8511-726d988f7a03, 24544a5d-0cf5-a099-b57c-6e0843a40532 +9NDC 62756-091, 70121-1467, 70700-315 +12Application ANDA210761, ANDA215397, ANDA210227 +5
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 1 mL in 1 vial, single-dose | 55150-329-01 | EugiaIndia | 22 August 2022 |
| 25 vial, single-dose in 1 carton / 1 mL in 1 vial, single-dose | 55150-329-25 | EugiaIndia | 22 August 2022 |
| 1 syringe in 1 carton / 1 mL in 1 syringe | 55150-330-01 | EugiaIndia | 31 August 2022 |
| 1 vial, single-dose in 1 carton / 1 mL in 1 vial, single-dose | 62756-090-40 | Sun Pharmaceutical IndustriesIndia | 4 May 2019 |
| 25 vial, single-dose in 1 carton / 1 mL in 1 vial, single-dose | 62756-090-45 | Sun Pharmaceutical IndustriesIndia | 4 May 2019 |
| 1 syringe in 1 carton / 1 mL in 1 syringe | 62756-091-40 | Sun Pharmaceutical IndustriesIndia | 1 May 2019 |
| 1 vial in 1 carton / 1 mL in 1 vial | 70121-1467-2 | Amneal Pharmaceuticals | 13 June 2023 |
| 25 vial in 1 carton / 1 mL in 1 vial | 70121-1467-5 | Amneal Pharmaceuticals | 13 June 2023 |
| 1 syringe, glass in 1 carton / 1 mL in 1 syringe, glass | 70121-1480-1 | Amneal Pharmaceuticals | 13 June 2023 |
| 1 vial in 1 carton / 1 mL in 1 vial | 60219-1467-1 | Amneal Pharmaceuticals NY | 10 June 2025 |
| 25 vial in 1 carton / 1 mL in 1 vial | 60219-1467-2 | Amneal Pharmaceuticals NY | 10 June 2025 |
| 1 vial in 1 carton / 1 mL in 1 vial | 24201-150-01 | Hikma Pharmaceuticals | 1 May 2023 |
| 25 vial in 1 carton / 1 mL in 1 vial | 24201-150-25 | Hikma Pharmaceuticals | 1 May 2023 |
| 25 vial in 1 carton / 1 mL in 1 vial | 67457-887-01 | Mylan Institutional | 12 October 2018 |
| 1 vial in 1 carton / 1 mL in 1 vial | 67457-887-99 | Mylan Institutional | 12 October 2018 |
| 25 vial in 1 carton / 1 mL in 1 vial | 70700-315-25 | Xiromed | 12 March 2024 |
| 1 vial in 1 carton / 1 mL in 1 vial | 70700-315-27 | Xiromed | 12 March 2024 |
| 1 vial in 1 carton / 1 mL in 1 vial | 50090-5619-0 | A-S Medication Solutions | 25 August 2021 |
| 1 syringe in 1 carton / 1 mL in 1 syringe | 50090-5925-0 | A-S Medication Solutions | 25 February 2022 |
| 25 vial in 1 carton / 1 mL in 1 vial | 66993-370-25 | Prasco Laboratories | 6 July 2021 |
| 1 vial in 1 carton / 1 mL in 1 vial | 66993-370-83 | Prasco Laboratories | 12 July 2021 |
| 1 syringe in 1 carton / 1 mL in 1 syringe | 66993-371-79 | Prasco Laboratories | 21 October 2021 |
| 1 syringe, glass in 1 carton / 1 mL in 1 syringe, glass | 70518-4324-0 | Remedyrepack | 1 April 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 18 June 1959 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Medroxyprogesterone 150 mg/1 mL injectable suspension.
Other strengths and forms of Medroxyprogesterone
Clinical summary
Medroxyprogesterone is a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. MedsAcross supplies Medroxyprogesterone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MedroxyprogesteroneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Provera prescribing information (Pharmacia & Upjohn) · U.S. National Library of Medicine, DailyMed
Need Medroxyprogesterone 150 mg/1 mL injectable suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.